Other endocrine disorders (E34) ICD-10-CM
The E34 code range covers other endocrine disorders with 23 ICD-10-CM diagnosis codes. 18 of them are billable and valid for claim submission in fiscal year 2027, and the category headers group them but cannot themselves be billed.
Type 1 Excludes
A type 1 excludes note is a pure excludes note. It means "NOT CODED HERE!" An Excludes1 note indicates that the code excluded should never be used at the same time as the code above the Excludes1 note. An Excludes1 is used when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
- pseudohypoparathyroidism E20.1
Codes in the E34 Range 23 codes · 18 billable
- E34 Other endocrine disordersNon-billable
- E34.0 Carcinoid syndromeNon-billable
- E34.00 Carcinoid syndrome, unspecified
- E34.01 Carcinoid heart syndrome
- E34.09 Other carcinoid syndrome
- E34.1 Other hypersecretion of intestinal hormones
- E34.2 Ectopic hormone secretion, not elsewhere classified
- E34.3 Short stature due to endocrine disorderNon-billable
- E34.30 Short stature due to endocrine disorder, unspecified
- E34.31 Constitutional short stature
- E34.32 Genetic causes of short statureNon-billable
- E34.321 Primary insulin-like growth factor-1 (IGF-1) deficiency
- E34.322 Insulin-like growth factor-1 (IGF-1) resistance
- E34.328 Other genetic causes of short stature
- E34.329 Unspecified genetic causes of short stature
- E34.39 Other short stature due to endocrine disorder
- E34.4 Constitutional tall stature
- E34.5 Androgen insensitivity syndromeNon-billable
- E34.50 Androgen insensitivity syndrome, unspecified
- E34.51 Complete androgen insensitivity syndrome
- E34.52 Partial androgen insensitivity syndrome
- E34.8 Other specified endocrine disorders
- E34.9 Endocrine disorder, unspecified
Clinical Terms in This Code Range
Definitions from the National Library of Medicine for conditions coded in the E34 range.
Androgen-Insensitivity Syndrome
A disorder of sexual development transmitted as an X-linked recessive trait. These patients have a karyotype of 46,XY with end-organ resistance to androgen due to mutations in the androgen receptor (RECEPTORS, ANDROGEN) gene. Severity of the defect in receptor quantity or quality correlates with their phenotypes. In these genetic males, the phenotypic spectrum ranges from those with normal female external genitalia, through those with genital ambiguity as in Reifenstein Syndrome, to that of a normal male with INFERTILITY.
Carcinoid Syndrome
A syndrome characterized by signs and symptoms caused by advanced carcinoid tumors. They include skin flushing, diarrhea, wheezing, and tachycardia.
Donohue Syndrome
Rare autosomal recessive syndrome of extreme insulin resistance due to mutations in the binding domain of INSULIN RECEPTOR. Clinical features include severe intrauterine and postnatal growth restriction, characteristic dysmorphic FACIES; HIRSUTISM; VIRILIZATION; multiple endocrine abnormalities, and early death.
Dwarfism
A genetic or pathological condition that is characterized by short stature and undersize. Abnormal skeletal growth usually results in an adult who is significantly below the average height.
Endocrine Disorder
A non-neoplastic or neoplastic disorder that affects the endocrine glands.
Familial Idiopathic Short Stature
Idiopathic short stature in a child when either one or both parents is short in stature.
Familial Idiopathic Tall Stature
Idiopathic tall stature in a child when either one or both parents is tall in stature.
Progeria
An abnormal congenital condition, associated with defects in the LAMIN TYPE A gene, which is characterized by premature aging in children, where all the changes of cell senescence occur. It is manifested by premature graying; hair loss; hearing loss (DEAFNESS); cataracts (CATARACT); ARTHRITIS; OSTEOPOROSIS; DIABETES MELLITUS; atrophy of subcutaneous fat; skeletal hypoplasia; elevated urinary HYALURONIC ACID; and accelerated ATHEROSCLEROSIS. Many affected individuals develop malignant tumors, especially SARCOMA.
Reifenstein Syndrome
A disorder also known as partial androgen insensitivity syndrome (PAIS). These patients exhibit partial resistance to androgenic and metabolic effects of TESTOSTERONE.
Testicular Feminization
A disorder also known as complete androgen insensitivity syndrome (CAIS). The 46,XY genetic male totally lacks androgen responsiveness in the target organs thus exhibits a female phenotype.
About the E34 Code Range
Other endocrine disorders include conditions involving hormone secretion, height, and androgen insensitivity.
E34.0 separates carcinoid heart syndrome from other or unspecified carcinoid syndrome. E34.1 describes excess intestinal hormone secretion, while E34.2 describes hormone secretion outside its usual location.
E34.3 groups short height due to an endocrine disorder. Its subdivisions distinguish constitutional short stature, genetic causes, and other or unspecified causes. Genetic causes split further into insulin-like growth factor-1 deficiency, resistance, and other or unspecified genetic causes. E34.4 describes constitutional tall stature.
E34.5 separates complete, partial, and unspecified androgen insensitivity syndrome. E34.8 and E34.9 distinguish other specified endocrine disorders from an unspecified endocrine disorder.
Questions About This Page
How many billable codes are in the E34 range?
Of the 23 codes in this range, 18 are billable and valid for claim submission from October 1, 2026 through September 30, 2027. Category header codes group them but cannot be reported on claims.
What does the E34 range classify?
The range classifies other endocrine disorders. Each code links to its own reference page with billing status, MS-DRG grouping, coding notes, and clinical information.
Related References
Source: CMS FY 2027 ICD-10-CM Tabular List and order file, effective October 1, 2026 through September 30, 2027.
